Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin.

Blood
Pierre SaviJean-Marc Herbert

Abstract

Heparin-induced thrombocytopenia (HIT) is a complication of heparin therapy caused by antibodies against a complex of platelet factor 4 and heparin. Fondaparinux (Arixtra) is a new synthetic selective factor Xa inhibitor. We performed a serologic study to determine the cross-reactivity of HIT sera with fondaparinux. Using a prospective, blinded study design, 39 clinically and serologically confirmed sera from patients with HIT and 15 control sera were sent to 3 different laboratories, each of which specialized in a particular HIT assay. These include the serotonin release assay, heparin-induced platelet agglutination assay, and platelet aggregation assay. Two of 82 assays (2.4%) performed in the presence of control sera were positive, both with unfractionated heparin. In the presence of HIT sera, 75 of 94 (79.8%) evaluable assays were positive with unfractionated heparin; fondaparinux was significantly (P < .001) less reactive than unfractionated heparin, only 3 of 91 evaluable assays (3.3%) being positive. Using flow cytometry, unlike unfractionated heparin, fondaparinux did not induce the binding of PAC1 and anti-CD62 monoclonal antibodies or of annexin V to platelets with HIT sera. Together, these results suggest that fondap...Continue Reading

References

Oct 1, 1996·British Journal of Haematology·P HorsewoodJ G Kelton
Mar 1, 1997·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·J AmiralD Meyer
Mar 22, 2000·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·S AhmadJ Fareed
Mar 3, 2001·The New England Journal of Medicine·A G TurpieUNKNOWN Pentasaccharide Investigators
Jan 17, 2002·The New England Journal of Medicine·B I ErikssonUNKNOWN Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study
Jan 17, 2002·The New England Journal of Medicine·K A BauerUNKNOWN Steering Committee of the Pentasaccharide in Major Knee Surgery Study
Jun 7, 2002·Lancet·Michael Rud LassenUNKNOWN European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee
Jun 11, 2003·Archives of Internal Medicine·Bengt I ErikssonUNKNOWN PENTasaccharide in HIp-FRActure Surgery Plus Investigators

❮ Previous
Next ❯

Citations

Jun 13, 2006·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·Emmanuel de MaistreDominique Lasne
Feb 14, 2006·Journal of Thrombosis and Thrombolysis·Sarah A Spinler
Nov 30, 2006·Journal of Thrombosis and Thrombolysis·Andrew F ShorrTheodore E Warkentin
Nov 24, 2007·Journal of Thrombosis and Thrombolysis·Laura Elizabeth HappeMatt William Sarnes
Jul 6, 2010·Current Opinion in Hematology·Karen M Hook, Charles S Abrams
Oct 6, 2005·Thrombosis Journal·Massimo Franchini
Nov 15, 2011·Circulation Journal : Official Journal of the Japanese Circulation Society·Norikazu YamadaMasaaki Ito
Jun 9, 2009·Clinical Interventions in Aging·Helia Robert-EbadiMarc Righini
Nov 7, 2006·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Peter M Nilsson
Aug 6, 2008·World Journal of Gastroenterology : WJG·Gudrun Scheving ThorsteinssonThomas H Casswall
Mar 22, 2014·Drug Discoveries & Therapeutics·Zhang LiuFengshan Wang
Feb 3, 2006·Intensive Care Medicine·H M Oudemans-van StraatenM R C Schetz
Aug 9, 2005·Hematology·K H M Kuo, M J Kovacs
Sep 16, 2010·Nature Reviews. Cardiology·Josien van EsHarry R Büller
Mar 12, 2013·Carbohydrate Research·Feng LinYing Zhou
Oct 20, 2005·Current Opinion in Cardiology·Simon J McRae, Jeffrey S Ginsberg
Mar 15, 2006·Current Opinion in Anaesthesiology·Erik Vandermeulen
Mar 21, 2006·Current Opinion in Anaesthesiology·Johann MotschBernd W Böttiger
Dec 10, 2009·Current Opinion in Anaesthesiology·Jerrold H Levy, Anne M Winkler
Nov 19, 2010·Expert Review of Hematology·Theodore E Warkentin
Jun 1, 2007·Expert Review of Pharmacoeconomics & Outcomes Research·William E Wade, William J Spruill
Feb 17, 2007·Expert Opinion on Investigational Drugs·Jeffrey I Weitz, Lori-Ann Linkins
Jul 19, 2005·Expert Opinion on Investigational Drugs·Jeanine M WalengaJawed Fareed
Mar 25, 2009·Expert Opinion on Drug Safety·Theodore E Warkentin, Andreas Greinacher
Feb 2, 2006·Expert Opinion on Pharmacotherapy·William H Matthai
Jun 15, 2007·Expert Opinion on Pharmacotherapy·Simon J McRae, John W Eikelboom
Dec 8, 2009·Scandinavian Cardiovascular Journal : SCJ·Maya LandenhedHenrik Bjursten
May 25, 2013·Clinics in Laboratory Medicine·Kisti P FullerAnne-Marie Prabulos
May 30, 2013·Hematology/oncology Clinics of North America·Grace M Lee, Gowthami M Arepally
Jan 19, 2016·Journal of Thrombosis and Thrombolysis·Maureen A SmytheAnn K Wittkowsky
Mar 28, 2009·International Journal of Cardiology·Neykova AnnaKirsch Matthias
Jan 8, 2008·Pathologie-biologie·C Garcia HejlV Foissaud
Nov 13, 2007·Thrombosis Research·S Middeldorp
Aug 18, 2005·Seminars in Thoracic and Cardiovascular Surgery·Eleanor S Pollak, Charles S Abrams
Jan 30, 2007·Hematology/oncology Clinics of North America·Jerrold H Levy, Marcie J Hursting
May 9, 2006·Critical Care Clinics·Erik R Vandendries, Reed E Drews
May 26, 2012·Thrombosis and Haemostasis·Theodore E WarkentinDanielle K Griffin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibodies: Agglutination

Antibody-mediated agglutination is the clumping of cells in the presence of antibody, which binds multiple cells together. This enhances the clearance of pathogens. Find the latest research on antibody-mediated agglutination here.